Administration of 6 Units Insulin Lispro in DKA
In a 60-kg adult with diabetic ketoacidosis, administer 6 units of insulin lispro subcutaneously, then reassess blood glucose and ketone levels 3 hours later to determine if additional dosing is needed.
Route and Technique
Based on the most recent guideline evidence, subcutaneous administration is appropriate for mild-to-moderate DKA 1. The specific protocol from the 2018 Anaesthesia guidelines provides clear direction:
- Give 6 IU (international units) of ultra-rapid analogue subcutaneously 1
- This dose applies when pre-prandial glycemia is ≥16.5 mmol/L (≥3 g/L or ≥297 mg/dL) with ketosis present
- Measure blood glucose 3 hours later and reassess ketosis status 1
Injection Site Selection
Per FDA labeling for insulin lispro, inject subcutaneously into 2:
- Stomach area (abdomen) - preferred site
- Buttocks
- Upper legs (thighs)
- Upper arms
Rotate injection sites within the chosen area to prevent lipodystrophy and localized cutaneous amyloidosis. Avoid areas with pits, thickened skin, lumps, tenderness, bruising, or scarring 2.
Ketosis Severity Determines Next Steps
The 2018 guideline provides an algorithmic approach based on ketone levels 1:
If Ketonuria = 1+ (or ketonemia 0.5-1.5 mmol/L):
- Give 6 IU ultra-rapid analogue SC
- Measure blood glucose AND check if ketosis still present 3 hours later
- Repeat dosing as needed based on response
If Ketonuria ≥ 2+ (or ketonemia ≥1.5 mmol/L):
- Transfer to ICU for IV insulin infusion therapy 1
- This represents more severe DKA requiring continuous IV insulin
Evidence Supporting Subcutaneous Approach
Multiple studies demonstrate that subcutaneous rapid-acting insulin analogues are equally effective as IV regular insulin for mild-to-moderate DKA 3, 4, 5:
- Time to DKA resolution is comparable (10-11 hours for both routes) 5
- Hypoglycemia rates are similar or lower with SC administration 3, 5
- SC protocols allow management outside ICU settings, reducing costs by 39% 5
- A 2025 study showed combining basal insulin (glargine 0.2 units/kg) with rapid-acting insulin (lispro 0.2 units/kg initially, then 0.1-0.2 units/kg every 3 hours) achieved 90% DKA resolution within 12 hours 6
Critical Monitoring Requirements
After administering the 6 units:
- Check blood glucose at 3 hours 1
- Reassess ketone levels (urine or blood) at 3 hours 1
- Monitor for hypoglycemia (blood glucose <70 mg/dL)
- Monitor potassium levels - insulin drives potassium intracellularly 7, 8
Common Pitfalls to Avoid
Do not use IV route reflexively - For mild-to-moderate DKA without severe acidosis (pH >6.9), SC administration is appropriate and evidence-based 7, 9, 8
Do not skip the 3-hour reassessment - The guideline specifically requires checking both glucose AND ketosis status at 3 hours to guide subsequent management 1
Do not ignore ketone trends - If ketosis worsens or fails to improve despite glucose normalization, escalate to IV insulin 1
Ensure adequate hydration - Insulin therapy must be accompanied by appropriate fluid resuscitation 7, 8
Monitor potassium closely - Supplement potassium as needed since insulin causes intracellular shift 7, 8
When to Escalate to IV Insulin
Transfer to ICU for continuous IV insulin infusion if 1:
- Ketonemia ≥1.5 mmol/L or ketonuria ≥2+
- pH <6.9 (consider bicarbonate therapy as well) 7, 8
- Altered mental status or severe dehydration
- Lack of improvement in ketosis after 3 hours of SC insulin
- Patient unable to tolerate SC injections
The 2018 guideline evidence provides the most specific and practical approach for this exact clinical scenario, making subcutaneous administration of 6 units insulin lispro with 3-hour reassessment the appropriate initial management strategy 1.